Q2 2025 · 13F-HR
RA CAPITAL MANAGEMENT, L.P.holdings as filed
Filed 2025-08-14 · accession 0001104659-25-078691
$5.94B
Reported value
63
Positions
2025-06-30
Period end
The Brief · RA CAPITAL MANAGEMENT, L.P. · Q2 2025
AI · grounded in 13F
RA CAPITAL MANAGEMENT, L.P. established a new position in ASCENDIS PHARMA A/S - ADR ASNDUSD valued at $1.77B. The fund also initiated new stakes in VAXCYTE INC PCVX for $389M and RHYTHM PHARMACEUTICALS INC RYTM for $351M. Other new additions include JANUX THERAPEUTICS INC JANX at $258M and AVIDITY BIOSCIENCES INC RNAGBP at $206M. The fund ended the period with 63 positions and total AUM of $5.94B.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S - ADR | $1.77B | 29.9% | 10,281,496 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $389.0M | 6.55% | 11,965,991 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $351.4M | 5.92% | 5,561,359 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $258.5M | 4.35% | 11,189,693 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $206.4M | 3.48% | 7,266,031 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $200.0M | 3.37% | 3,036,527 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $195.3M | 3.29% | 19,889,683 | Common | SOLE |
| 82835W108 | SPRY | ARS PHARMACEUTICALS INC | $189.5M | 3.19% | 10,860,977 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA CO NV | $183.6M | 3.09% | 10,138,938 | Common | SOLE |
| 829401108 | SION | SIONNA THERAPEUTICS INC | $181.2M | 3.05% | 10,445,322 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $163.9M | 2.76% | 3,365,523 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $129.8M | 2.19% | 9,902,633 | Common | SOLE |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $122.5M | 2.06% | 4,178,823 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $118.3M | 1.99% | 18,202,009 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $116.7M | 1.97% | 12,198,625 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $93.6M | 1.58% | 7,676,697 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $92.5M | 1.56% | 9,714,392 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $85.1M | 1.43% | 60,379,366 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $83.5M | 1.41% | 1,577,106 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $83.2M | 1.40% | 6,147,280 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $73.9M | 1.25% | 6,995,858 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $70.4M | 1.19% | 10,229,099 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $64.6M | 1.09% | 6,955,993 | Common | SOLE |
| 929033108 | VOR | VOR BIOPHARMA INC | $64.2M | 1.08% | 39,646,039 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $54.4M | 0.92% | 23,555,648 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $53.4M | 0.90% | 2,866,733 | Common | SOLE |
| 78349D107 | RXST | RXSIGHT INC | $48.1M | 0.81% | 3,702,967 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $40.6M | 0.68% | 2,538,925 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HOLDING CORP | $40.3M | 0.68% | 1,136,453 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $39.0M | 0.66% | 31,419,267 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $31.5M | 0.53% | 1,517,418 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $28.3M | 0.48% | 5,811,323 | Common | SOLE |
| 59267L107 | — | METSERA INC | $19.2M | 0.32% | 675,525 | Common | SOLE |
| 61023L207 | MNPR | MONOPAR THERAPEUTICS INC | $18.3M | 0.31% | 511,207 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $17.9M | 0.30% | 10,805,129 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $17.5M | 0.29% | 6,045,351 | Common | SOLE |
| 00509G209 | ABOS | ACUMEN PHARMACEUTICALS INC | $17.3M | 0.29% | 14,932,063 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $17.0M | 0.29% | 848,986 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $17.0M | 0.29% | 1,150,000 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $16.9M | 0.29% | 4,563,211 | Common | SOLE |
| 433313103 | HNGE | HINGE HEALTH INC-A | $15.5M | 0.26% | 300,000 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $14.9M | 0.25% | 9,853,302 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $11.9M | 0.20% | 10,689,545 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $10.6M | 0.18% | 1,062,326 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $10.2M | 0.17% | 2,000,000 | Common | SOLE |
| 004890109 | ACRV | ACRIVON THERAPEUTICS INC | $9.9M | 0.17% | 8,340,508 | Common | SOLE |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $9.7M | 0.16% | 3,566,338 | Common | SOLE |
| 03969F109 | RCUS | ARCUS BIOSCIENCES INC | $9.3M | 0.16% | 1,136,364 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAPITAL SOLUTIONS | $8.0M | 0.13% | 750,000 | Common | SOLE |
| 68170A108 | OMDA | OMADA HEALTH INC | $7.3M | 0.12% | 400,000 | Common | SOLE |
| 95075A107 | HOWL | WEREWOLF THERAPEUTICS INC | $7.3M | 0.12% | 6,681,307 | Common | SOLE |
| 08659B102 | BBNX | BETA BIONICS INC | $7.3M | 0.12% | 500,000 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $6.0M | 0.10% | 2,661,331 | Common | SOLE |
| 88025U109 | TXG | 10X GENOMICS INC-CLASS A | $5.5M | 0.09% | 475,343 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $5.4M | 0.09% | 602,626 | Common | SOLE |
| 81663L200 | WGS | GENEDX HOLDINGS CORP | $5.4M | 0.09% | 58,044 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $4.7M | 0.08% | 932,973 | Common | SOLE |
| 007002108 | TORCEUR | ADICET BIO INC | $4.6M | 0.08% | 7,541,000 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $4.3M | 0.07% | 377,841 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTIC INC | $3.1M | 0.05% | 1,039,295 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA CO NV-27 | $2.7M | 0.04% | 333,333 | Common | SOLE |
| 00404A109 | ACHC | ACADIA HEALTHCARE CO INC | $2.0M | 0.03% | 89,262 | Common | SOLE |
| N44821101 | IFRX | INFLARX NV | $1.6M | 0.03% | 1,973,233 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.